Don’t Miss Out On These Tantalizing Sohn Conference Stock Pitches

Christopher Lord of Criterion Capital pitched Mercadolibre Inc (NASDAQ:MELI) at the Sohn Conference, which his fund did not have a position in as of June 30. Lord expressed that the company has a management team that he knows very well, and that they have a large and unpenetrated addressable market (TAM of about $1.2 trillion).

The e-commerce company is the largest in Latin America, a region with growing smartphone and broadband internet penetration, as well as a growing middle class. Some analysts aren’t thrilled with the company’s continued use of free shipping to drive revenue growth, though others see it as a strong move to gain market share long-term in exchange for near-term profit, a strategy that worked out pretty well for another e-commerce company, Amazon.com, Inc. (NASDAQ:AMZN).

Carl Kawaja of Capital Group pitched Sony Corp (ADR) (NYSE:SNE) during the event, predicting that the Japanese electronics giant is on its way to becoming a significant company again after several lean years. Kawaja believes that Sony’s management team is much stronger than it’s been in the past and that it’s beginning to capitalize on its huge opportunities in gaming, music, and sensors. Kawaja believes that the market is undervaluing Sony because of the breadth of its businesses, but that investors should expect 50% upside.

Lastly is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), which was pitched by Oleg Nodelman of EcoR1 Capital. Nodelman is bullish on Ironwood’s Linzess, the first approved treatment that targets Irritable Bowel Syndrome with Constipation (IBS‑C) and Chronic Idiopathic Constipation (CIC) by calming pain-sensing nerves and promoting accelerated bowel movements.

The treatment has an addressable market of 40 million Americans and is being marketed by Allergan. The treatment’s ad campaign was the lone winner of an Effie award earlier this year, which are awarded to pharma companies for launching ad campaigns that successfully drive results. The “Tell Me Something I Don’t Know” campaign is credited with increasing Linzess’ prescription volume by 13% year-over-year.

Nodelman believes that Ironwood’s pipeline of seven other treatments is largely being unaccounted for by the market and thinks the stock could jump by as much as 1,000%.

Disclosure: None